Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas

Arie Perry, Kari Anderl, Tom J. Borell, David W. Kimmel, Chiao H. Wang, Judith R. O'Fallon, Burt G.F. Feuerstein, Bernd W. Scheithauer, Robert B. Jenkins

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Inactivation of the p53 gene is a common early event of astrocytoma tumorigenesis. Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. We obtained smear preparations from 96 diffuse gliomas and 10 nonneoplastic specimens. Dual-color fluorescence in situ hybridizations using paired probes for CEN9/p16, CEN8/RB, CEN17/p53, and CEN12/CDK4 were performed and revealed expected frequencies of abnormalities, except for p53 losses, which were low (7%). The latter supports the concept that p53 inactivation usually occurs by mitotic recombination. Detected abnormalities of the p16/RB/CDK4 pathway were highly associated with astrocytic differentiation and were univariately associated with decreased patient survival. However, only patient age and histologic classification retained statistical significance on multivariate analysis. We conclude that in diffuse gliomas, p16/RB/CDK4 abnormalities are markers of astrocytic phenotype. Thus, their detection by fluorescence in situ hybridization may have diagnostic usefulness in cases with equivocal morphologic features. Although our numbers are small, we find no additional prognostic significance to these genetic abnormalities once age, grade, and oligodendroglial histology are taken into account.

Original languageEnglish (US)
Pages (from-to)801-809
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume112
Issue number6
StatePublished - 1999
Externally publishedYes

Fingerprint

Retinoblastoma Genes
Retinoblastoma
Gene Amplification
p53 Genes
Gene Deletion
Fluorescence In Situ Hybridization
Glioma
Astrocytoma
Genetic Recombination
Histology
Carcinogenesis
Multivariate Analysis
Color
Phenotype
Survival

Keywords

  • Astrocytoma
  • Cyclin-dependent kinases
  • Fluorescence in situ hybridization
  • Glioma
  • p16 gene
  • p53 gene
  • Retinoblastoma gene

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Perry, A., Anderl, K., Borell, T. J., Kimmel, D. W., Wang, C. H., O'Fallon, J. R., ... Jenkins, R. B. (1999). Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. American Journal of Clinical Pathology, 112(6), 801-809.

Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. / Perry, Arie; Anderl, Kari; Borell, Tom J.; Kimmel, David W.; Wang, Chiao H.; O'Fallon, Judith R.; Feuerstein, Burt G.F.; Scheithauer, Bernd W.; Jenkins, Robert B.

In: American Journal of Clinical Pathology, Vol. 112, No. 6, 1999, p. 801-809.

Research output: Contribution to journalArticle

Perry, A, Anderl, K, Borell, TJ, Kimmel, DW, Wang, CH, O'Fallon, JR, Feuerstein, BGF, Scheithauer, BW & Jenkins, RB 1999, 'Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas', American Journal of Clinical Pathology, vol. 112, no. 6, pp. 801-809.
Perry, Arie ; Anderl, Kari ; Borell, Tom J. ; Kimmel, David W. ; Wang, Chiao H. ; O'Fallon, Judith R. ; Feuerstein, Burt G.F. ; Scheithauer, Bernd W. ; Jenkins, Robert B. / Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. In: American Journal of Clinical Pathology. 1999 ; Vol. 112, No. 6. pp. 801-809.
@article{4c4aedfa570d426598e44b289629308b,
title = "Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas",
abstract = "Inactivation of the p53 gene is a common early event of astrocytoma tumorigenesis. Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. We obtained smear preparations from 96 diffuse gliomas and 10 nonneoplastic specimens. Dual-color fluorescence in situ hybridizations using paired probes for CEN9/p16, CEN8/RB, CEN17/p53, and CEN12/CDK4 were performed and revealed expected frequencies of abnormalities, except for p53 losses, which were low (7{\%}). The latter supports the concept that p53 inactivation usually occurs by mitotic recombination. Detected abnormalities of the p16/RB/CDK4 pathway were highly associated with astrocytic differentiation and were univariately associated with decreased patient survival. However, only patient age and histologic classification retained statistical significance on multivariate analysis. We conclude that in diffuse gliomas, p16/RB/CDK4 abnormalities are markers of astrocytic phenotype. Thus, their detection by fluorescence in situ hybridization may have diagnostic usefulness in cases with equivocal morphologic features. Although our numbers are small, we find no additional prognostic significance to these genetic abnormalities once age, grade, and oligodendroglial histology are taken into account.",
keywords = "Astrocytoma, Cyclin-dependent kinases, Fluorescence in situ hybridization, Glioma, p16 gene, p53 gene, Retinoblastoma gene",
author = "Arie Perry and Kari Anderl and Borell, {Tom J.} and Kimmel, {David W.} and Wang, {Chiao H.} and O'Fallon, {Judith R.} and Feuerstein, {Burt G.F.} and Scheithauer, {Bernd W.} and Jenkins, {Robert B.}",
year = "1999",
language = "English (US)",
volume = "112",
pages = "801--809",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas

AU - Perry, Arie

AU - Anderl, Kari

AU - Borell, Tom J.

AU - Kimmel, David W.

AU - Wang, Chiao H.

AU - O'Fallon, Judith R.

AU - Feuerstein, Burt G.F.

AU - Scheithauer, Bernd W.

AU - Jenkins, Robert B.

PY - 1999

Y1 - 1999

N2 - Inactivation of the p53 gene is a common early event of astrocytoma tumorigenesis. Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. We obtained smear preparations from 96 diffuse gliomas and 10 nonneoplastic specimens. Dual-color fluorescence in situ hybridizations using paired probes for CEN9/p16, CEN8/RB, CEN17/p53, and CEN12/CDK4 were performed and revealed expected frequencies of abnormalities, except for p53 losses, which were low (7%). The latter supports the concept that p53 inactivation usually occurs by mitotic recombination. Detected abnormalities of the p16/RB/CDK4 pathway were highly associated with astrocytic differentiation and were univariately associated with decreased patient survival. However, only patient age and histologic classification retained statistical significance on multivariate analysis. We conclude that in diffuse gliomas, p16/RB/CDK4 abnormalities are markers of astrocytic phenotype. Thus, their detection by fluorescence in situ hybridization may have diagnostic usefulness in cases with equivocal morphologic features. Although our numbers are small, we find no additional prognostic significance to these genetic abnormalities once age, grade, and oligodendroglial histology are taken into account.

AB - Inactivation of the p53 gene is a common early event of astrocytoma tumorigenesis. Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. We obtained smear preparations from 96 diffuse gliomas and 10 nonneoplastic specimens. Dual-color fluorescence in situ hybridizations using paired probes for CEN9/p16, CEN8/RB, CEN17/p53, and CEN12/CDK4 were performed and revealed expected frequencies of abnormalities, except for p53 losses, which were low (7%). The latter supports the concept that p53 inactivation usually occurs by mitotic recombination. Detected abnormalities of the p16/RB/CDK4 pathway were highly associated with astrocytic differentiation and were univariately associated with decreased patient survival. However, only patient age and histologic classification retained statistical significance on multivariate analysis. We conclude that in diffuse gliomas, p16/RB/CDK4 abnormalities are markers of astrocytic phenotype. Thus, their detection by fluorescence in situ hybridization may have diagnostic usefulness in cases with equivocal morphologic features. Although our numbers are small, we find no additional prognostic significance to these genetic abnormalities once age, grade, and oligodendroglial histology are taken into account.

KW - Astrocytoma

KW - Cyclin-dependent kinases

KW - Fluorescence in situ hybridization

KW - Glioma

KW - p16 gene

KW - p53 gene

KW - Retinoblastoma gene

UR - http://www.scopus.com/inward/record.url?scp=0033491737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033491737&partnerID=8YFLogxK

M3 - Article

C2 - 10587703

AN - SCOPUS:0033491737

VL - 112

SP - 801

EP - 809

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -